video

Oncology

Interview at ESMO 2025 with Liam Tremble

ESMO25: Transforming the cancer immunotherapy field, with Po...

Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.

Oncology

ESMO25: On getting ahead of cancer, with J&J's Henar Hevia &...

In conversation with Johnson & Johnson experts at ESMO 2025, discussing T-cell-redirecting bispecific antibodies and the future of immunotherapy.

Oncology

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

Digital

Agentic AI buoys all stakeholders in oncology, with Eron Kel...

At LSX 2025, Eron Kelly, CEO of Concert AI, discussed the work his Boston-based start-up is doing in oncology.

R&D

Interview at LSX 25 with Steffen Sebastian Bolz

A different approach to obesity treatment, with Steffen-Seba...

At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.

ESMO25: Transforming the cancer immunotherapy field, with Po...

ESMO25: On getting ahead of cancer, with J&J's Henar Hevia &...

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

Agentic AI buoys all stakeholders in oncology, with Eron Kel...

A different approach to obesity treatment, with Steffen-Seba...

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

video

Editor's Picks